Cariprazine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Cariprazine: From Schizophrenia and Bipolar Disorder to Retinal Dystrophy
One-Sentence Summary
Cariprazine is an antipsychotic originally used for schizophrenia and bipolar disorder (including manic episodes). The TxGNN model predicts it may be effective for retinal dystrophy with or without extraocular anomalies, but no clinical trials and no publications currently support this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia; bipolar disorder (including manic episodes). The Singapore licences carry no indication text, so this comes from the knowledge-graph indication data. |
| Predicted New Indication | Retinal dystrophy with or without extraocular anomalies |
| TxGNN Prediction Score | 98.70% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. From general pharmacology, cariprazine is a dopamine D3/D2 partial agonist and a serotonin 5-HT1A partial agonist. Its efficacy in schizophrenia and bipolar disorder comes from modulating these neurotransmitter systems.
The link to retinal dystrophy is weak. Dopamine signalling does play a role in retinal function, but retinal dystrophies are typically inherited degenerative disorders driven by genetic defects in photoreceptors or retinal pigment epithelium. A receptor-modulating antipsychotic is not expected to halt or reverse this degeneration. The high TxGNN score most likely reflects a pattern in the knowledge graph rather than a pharmacologically grounded prediction.
Other top-ranked predictions are also implausible. They include hydranencephaly, perisylvian polymicrogyria, a congenital disorder of glycosylation, Charcot-Marie-Tooth disease type 1G, atypical glycine encephalopathy and distal 17p13.3 microdeletion syndrome. These are structural, metabolic or genetic conditions that a neurotransmitter-receptor drug cannot correct. Three myopia entries (syndromic myopia, X-linked myopia, and myopia 26 X-linked female-limited) have a speculative link through retinal dopamine and eye growth. Cariprazine has not been tested for this, and these are genetic forms of myopia.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15746P | SYMVENU HARD CAPSULES 6MG | Capsule, gelatin coated | Not stated in the data compiled |
| SIN15745P | SYMVENU HARD CAPSULES 4.5MG | Capsule, gelatin coated | Not stated in the data compiled |
| SIN15744P | SYMVENU HARD CAPSULES 3MG | Capsule, gelatin coated | Not stated in the data compiled |
| SIN15743P | SYMVENU HARD CAPSULES 1.5MG | Capsule, gelatin coated | Not stated in the data compiled |
All four licences are valid single-ingredient oral products from Gedeon Richter Plc.
Safety Considerations
- Drug Interactions: The interaction screen returned 100 interacting drugs. The 20 shown in the data compiled for this report include three rated Major:
- Bupropion
- Morphine
- Clarithromycin
The rest are rated Moderate. They include:
- Antidiabetic drugs: acarbose, albiglutide, alogliptin, metformin, pioglitazone, canagliflozin, dapagliflozin, acetohexamide and chlorpropamide
- Anticholinergics: hyoscyamine, atropine, glycopyrronium and clidinium
- Others: aprepitant, dexamethasone, cimetidine and clotrimazole
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trials and no publications, so it sits at evidence level L5. The mechanistic link to retinal dystrophy is weak, since these disorders are genetically driven degenerative conditions. Exposing patients to a systemic antipsychotic with a major drug interaction profile cannot be justified on model output alone.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA, which block safety screening
- Detailed mechanism of action data
- Preclinical evidence, such as retinal degeneration models, showing a plausible effect of D3/D2 or 5-HT1A partial agonism
- A literature search for any supporting studies
- A review of whether another indication on the list has a more credible rationale, since none has any trial or literature support at present
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.